ClinicalTrials.gg
TerminatedNCT00328926Updated Aug 7, 2013Results posted

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

A Phase 4 interventional study of Luveris® 75 IU and Luveris® 25 IU in Hypogonadotropic Hypogonadism, sponsored by EMD Serono. Terminated at 1 site in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2013-08-07.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 4, Interventional, and Treatment

Why this study was terminated
Please see "Purpose" statement

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 185 studies in Hypogonadism with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Hypogonadism · United States.

Enrollment
135th of 154
11 · median 45
Started
2006
with 14 others
Phase 4
27 of 185
1 open now
Registered
32nd of 185
by date

Among the 185 studies in Hypogonadism with a site in United States, this one is the 135th largest by enrollment of the 154 interventional ones that give a count, is one of 15 that started in 2006, is one of 27 in phase 4, and was the 32nd registered.

Hypogonadism

320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.

Browse Hypogonadism studies →

Open to participants now

12 of the 185 studies in Hypogonadism with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Hypogonadism studies recruiting now, 9 (38%) set no upper age limit and 12 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Hypogonadism with a site in United States, or all of them as a file.
02

Study summary

Sponsor has decided to discontinue Luveris® in the United States (US) due to level of customer demand for this product, and not due to any efficacy or safety concerns.

Read the detailed description

To confirm the efficacy of the 75 IU dose of Luveris® compared to placebo when administered concomitantly with follitropin alfa for induction of clinical pregnancy in women with hypogonadotropic hypogonadism and profound LH deficiency (LH \<1.2 IU/L), and to study the efficacy of a lower dose (25 IU) of Luveris® compared to placebo when administered concomitantly with follitropin alfa for induction of follicular development in women with hypogonadotropic hypogonadism and profound LH deficiency (LH \<1.2 IU/L).

03

Conditions studied

  • Hypogonadotropic Hypogonadism

Browse trials for

Keywords

  • Hypogonadotropic Hypogonadism (LH <1.2 IU/L)
  • Placebo
  • Luveris® 75 IU
  • Luveris® 25 IU
  • Recombinant human chorionic gonadotropin (r-hCG)
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be premenopausal, between 18 and 40 years of age inclusive on the day of consent
  • Have a clinical history of hypogonadotropic hypogonadism (World health organization [WHO] Group I type of anovulation) on the basis of congenital or acquired hypothalamic or pituitary endocrine dysfunction in the presence of qualifying screening laboratories
  • Have no prior treatment cycles with gonadotropins or gonadotropin releasing hormone (GnRH) (gonadotropin naïve)
  • Have discontinued estrogen-progesterone replacement therapy at least one month before the screening procedure
  • Have primary or secondary amenorrhea
  • Have a negative progestin challenge test performed during Screening
  • Have the following hormonal values in a centrally analyzed fasting blood sample, drawn within 6 weeks before initiation of treatment:

    • Follicle-Stimulating Hormone (FSH): less than (\<)5 international unit per liter (IU/L)
    • Leutinizing hormone (LH): \<1.2 IU/L (a second Baseline serum LH level will be repeated two weeks after the initial LH draw)
    • Prolactin: \< 43.3 nanogram per milliliter (ng/mL) (\<1040 milli-international unit per liter [mIU/L])
    • Thyroid Stimulating Hormone (TSH): \<6.5 micro-international units per milliliter (mcIU/mL)
    • Free Thyroxin (T4): 0.8-1.8 nanogram per deciliter (ng/dL) (11-24 picomole per liter [pmol/L])
    • Testosterone: \<1.0 ng/mL (\<3.5 nanomole per liter [nmol/L])
  • Have an endovaginal pelvic ultrasound scan showing (i) no uterine abnormality, (ii) no ovarian tumor or cyst, and (iii) less than or equal to (=\<)13 small follicles (mean diameter =\<10 milliliter [mm]) on the largest section through each ovary
  • Have a normal cervical pap smear within 6 months of the initial visit
  • Where indicated, have a normal or unchanged computed tomography (CT) scan or nuclear magnetic resonance (NMR) scan of the hypothalamic pituitary region on file
  • Have a (BMI) between 18.4 and 31.4 kilogram per square meter (kg/m\^2)
  • Be willing and able to comply with the protocol for the duration of the study
  • Have given written prior to any study related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to her future medical care

Exclusion criteria

Exclusion Criteria:

  • Any medical condition which in the judgment of the investigator may interfere with the absorption, distribution, metabolism or excretion of the drug
  • Any pre-existing medical condition which would compromise the subject's ability to conceive in vivo or to successfully complete a pregnancy
  • Ongoing pregnancy
  • systemic disease (example: insulin-dependent diabetes mellitus, epilepsy, serious migraine, intermittent purpura, hepatic, renal or cardiovascular disease, serious corticoid-dependent asthma)
  • Known infection with (HIV), or C
  • Ovarian enlargement or cyst of unknown etiology
  • Abnormal gynecological bleeding of undetermined origin
  • Previous or current hormone dependent tumor
  • Known active substance abuse or eating disorder
  • Known central nervous system (CNS) Lesions: In cases where hypogonadotropic hypogonadism (HH) is secondary to a CNS lesion or its treatment
  • Exercise program exceeding 10 hours per week
  • Is planning to undergo in vitro fertilization, intracytoplasmic sperm injection or another assisted reproductive technology (ART) procedure, other than intrauterine insemination, in the course of a study treatment cycle
  • Currently undergoing treatment with psychotropic medication or with any other medication known to interfere with normal reproductive function (example: neuroleptics, dopamine antagonists)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
11 participants (actual)

Study arms

  • Active comparator
    Luveris® 75 IU

    Drug: Luveris® 75 IU · Drug: Recombinant human follicle stimulating hormone (r-hFSH) · Drug: Recombinant human chorionic gonadotropin (r-hCG)

  • Active comparator
    Luveris® 25 IU

    Drug: Luveris® 25 IU · Drug: Recombinant human follicle stimulating hormone (r-hFSH) · Drug: Recombinant human chorionic gonadotropin (r-hCG)

  • Placebo comparator
    Placebo

    Drug: Placebo · Drug: Recombinant human follicle stimulating hormone (r-hFSH) · Drug: Recombinant human chorionic gonadotropin (r-hCG)

Interventions

  • Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 75 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and estradiol \[E2\] levels). Total duration will be of 3 treatment cycles.

    Also known as: Lutropin alfa, Recombinant human luteinizing hormone (r-hLH)

  • Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 25 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.

    Also known as: Lutropin alfa, Recombinant human luteinizing hormone (r-hLH)

  • DrugPlacebo

    Placebo will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.

  • Fixed dose of recombinant human follicle stimulating hormone (r-hFSH, follitropin alfa) 75 to 150 IU will be administered subcutaneously for 7 days. After 7 days of treatment, if the subject response will suboptimal, based on follicular growth and serum E2 levels, follitropin alfa dose adjusted to maximal dose of 225 IU. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.

    Also known as: Follitropin alfa

  • When the follicular response will adequate, ovulation will be triggered by a single 250 microgram subcutaneous injection of recombinant human chorionic gonadotropin (r-hCG, choriogonadotropin alfa). Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.

    Also known as: Choriogonadotropin alfa

06

What researchers measure

Primary outcomes

  1. Time to Clinical Pregnancy

    Clinical pregnancy was defined as the presence of one or more fetal sac with fetal heart activity on the Day 35-42 post r-hCG ultrasound examination.

    Time frame: Stimulation Day 1 up to clinical pregnancy (Day 35-42 post r-hCG administration day [end of stimulation cycle {approximately 21 days}])

Secondary outcomes

  1. Percentage of Participants With Cumulative Clinical Pregnancy

    Clinical pregnancy was defined as the presence of one or more fetal sac with fetal heart activity on the Day 35-42 post r-hCG ultrasound examination. Cumulative clinical pregnancy referred to all clinical pregnancy that occurred during all the 3 treatment cycles.

    Time frame: Day 35-42 post r-hCG administration day (end of stimulation cycle [approximately 21 days])

  2. Percentage of Participants With Cumulative Ovulation

    Ovulation was defined as a mid-luteal phase progesterone (P4) level greater than or equal to (\>=) 10 nanogram per milliliter (ng/mL). Cumulative ovulation referred to all ovulations that occurred during all the 3 treatment cycles.

    Time frame: Recombinant human chorionic gonadotropin (r-hCG) administration day (end of stimulation cycle [approximately 21 days])

07

Results

Posted Jul 12, 2013

Participant flow

Participant flow — Overall Study
MilestoneLuveris® 75 IULuveris® 25 IUPlacebo
Started533
Completed301
Not completed232
Withdrew: Pregnancy210
Withdrew: Lost to follow-up010
Withdrew: Death001
Withdrew: In vitro fertilization treatment001
Withdrew: Lack of ovarian response010

Outcome measures

PrimaryTime to Clinical Pregnancy

Clinical pregnancy was defined as the presence of one or more fetal sac with fetal heart activity on the Day 35-42 post r-hCG ultrasound examination.

Time frame:
Stimulation Day 1 up to clinical pregnancy (Day 35-42 post r-hCG administration day [end of stimulation cycle {approximately 21 days}])
Reported as:
Median · Days
Time to Clinical Pregnancy
DaysLuveris® 75 IULuveris® 25 IUPlacebo
Time to Clinical Pregnancy71 (47 to 116)51 (51 to 51)103 (103 to 103)
SecondaryPercentage of Participants With Cumulative Clinical Pregnancy

Clinical pregnancy was defined as the presence of one or more fetal sac with fetal heart activity on the Day 35-42 post r-hCG ultrasound examination. Cumulative clinical pregnancy referred to all clinical pregnancy that occurred during all the 3 treatment cycles.

Time frame:
Day 35-42 post r-hCG administration day (end of stimulation cycle [approximately 21 days])
Reported as:
Number · Percentage of participants
Percentage of Participants With Cumulative Clinical Pregnancy
Percentage of participantsLuveris® 75 IULuveris® 25 IUPlacebo
Percentage of Participants With Cumulative Clinical Pregnancy60.033.333.3
SecondaryPercentage of Participants With Cumulative Ovulation

Ovulation was defined as a mid-luteal phase progesterone (P4) level greater than or equal to (\>=) 10 nanogram per milliliter (ng/mL). Cumulative ovulation referred to all ovulations that occurred during all the 3 treatment cycles.

Time frame:
Recombinant human chorionic gonadotropin (r-hCG) administration day (end of stimulation cycle [approximately 21 days])
Reported as:
Number · Percentage of participants
Percentage of Participants With Cumulative Ovulation
Percentage of participantsLuveris® 75 IULuveris® 25 IUPlacebo
Percentage of Participants With Cumulative Ovulation80.033.366.7

Adverse events

Collected over Stimulation Day 1 up to Day 35-42 post r-hCG administration day (end of stimulation cycle [approximately 21 days]). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Luveris® 75 IU—1/5 (20%)4/5 (80%)
Luveris® 25 IU—0/3 (0%)1/3 (33.3%)
Placebo—1/3 (33.3%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventLuveris® 75 IULuveris® 25 IUPlacebo
Pneumonia pneumococcalInfections and infestations0/50/31/3
Pneumonia streptococcalInfections and infestations0/50/31/3
Abortion missedPregnancy, puerperium and perinatal conditions1/50/30/3
Most frequent other events
Showing 10 of 34
Most frequent other events
EventLuveris® 75 IULuveris® 25 IUPlacebo
NauseaGastrointestinal disorders2/51/32/3
Abdominal distensionGastrointestinal disorders0/51/32/3
Adnexa uteri painReproductive system and breast disorders3/50/30/3
HeadacheNervous system disorders2/50/31/3
Uterine spasmReproductive system and breast disorders2/50/31/3
Ovarian cystReproductive system and breast disorders2/50/30/3
Ligament sprainInjury, poisoning and procedural complications2/50/30/3
DyspepsiaGastrointestinal disorders0/50/31/3
DysstasiaNervous system disorders0/50/31/3
MigraineNervous system disorders0/50/31/3

Baseline characteristics

Age Continuous
Age Continuous(years)Luveris® 75 IULuveris® 25 IUPlaceboTotal
Mean28.6 ± 2.534.3 ± 5.029.3 ± 3.830.4 ± 4.1
Sex: Female, Male
Sex: Female, Male(Participants)Luveris® 75 IULuveris® 25 IUPlaceboTotal
Female53311
Male0000
08

Study locations

1 site
  • U.S. Medical Information, 1-888-275-7376
    Rockland, Massachusetts 02370, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2006
First posted
May 24, 2006
Start
Mar 2006
Primary completionActual
May 2012
CompletionActual
May 2012
Results first posted
Jul 12, 2013
Last update
Aug 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00328926
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
May 24, 2006
Start date
Mar 2006
Primary completion
May 2012
Completion
May 2012
Results posted
Jul 12, 2013
Last update
Aug 7, 2013

Study contacts

Medical Responsible
study director · Merck Serono S.A., Geneva
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutropin alfa

Start the discussion